Quantum Pharma’s Colonis launches medical devices for side effects of cancer treatment

Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat some of the side effects of cancer treatment in patients.

Quantum Pharma is a growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors.

The first product in the range, Mucodis Oromucosal Spray for the treatment of oral mucositis, a painful inflammation of the mouth.

According to Quantum, the range initially comprises up to seven products that are used to treat the side effects of chemotherapy and radiotherapy, specifically the inflammation of different mucosal membranes of the body, including that of the mouth and rectum. The range will be marketed and sold in the UK under the Mucodis brand name.

Andy Scaife, CEO of Quantum Pharma, commented:

“We are excited to be making available the first product in the Mucodis® range. This range has the potential to make a difference for patients living with the side effects of cancer treatment commonly triggered by radiotherapy and chemotherapy. The launch of Mucodis® and the developments within this team mark a promising new chapter for both Niche Pharmaceuticals and the Group’s expansion into regulated products, with a number of further medical device and licensed product launches anticipated during the current financial year.”